Antibody binding specifically to pre-S1 of hepatitis B virus and use of the antibody
Provided are: an antibody binding specifically to a surface antigen, pre-S1, of a hepatitis B virus (HBV); a polynucleotide coating the antibody; an expression vector comprising the polynucleotide; a transformation agent comprising the expression vector; and use of the antibody in treating or preventing HBV infection and in detecting an HBV.
1. An antibody binding specifically to a surface antigen pre-S1 of hepatitis B virus (HBV), wherein the antibody comprises a heavy-chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO: 2; a heavy chain CDR2 set forth in SEQ ID NO: 24; and a heavy chain CDR3 set forth in SEQ ID NO: 21, and a light-chain variable region comprising a light chain CDR1 set forth in SEQ ID NO: 9; a light chain CDR2 set forth in SEQ ID NO: 27; and a light chain CDR3 set forth in SEQ ID NO: 13.
2. The antibody of claim 1 , wherein the antibody comprises a heavy-chain variable region set forth in SEQ ID NO: 30, and a light-chain variable region set forth in SEQ ID NO: 31.
3. An antibody binding specifically to a surface antigen pre-S1 of hepatitis B virus (HBV), wherein the antibody comprises a heavy-chain variable region set forth in SEQ ID NO: 23, and a light-chain variable region set forth in SEQ ID NO: 31.
4. The antibody of claim 1 , wherein the antibody is a humanized antibody.
5. A polynucleotide coding for the antibody defined in claim 1 .
6. An expression vector comprising the polynucleotide defined in claim 5 .
7. A non-human transformant comprising the expression vector defined in claim 6 .
8. A pharmaceutical composition for preventing or treating hepatitis B virus (HBV) infection, comprising the antibody defined in claim 1 .
9. The pharmaceutical composition of claim 8 , wherein the composition is for preventing or treating hepatitis B.
10. A method of providing information for diagnosis of hepatitis B virus (HBV) infection, comprising:
detecting a pre-S1 protein, which is present in a biological sample isolated from a subject suspected to have HBV infection, through an antigen-antibody reaction using the antibody defined in claim 1 .
11. The method of claim 10 , wherein the method is for providing information for diagnosis of hepatitis B.
12. A composition for detecting hepatitis B virus (HBV), comprising the antibody defined in claim 1 .
13. The composition of claim 12 , wherein the composition is for diagnosis of hepatitis B.
14. A kit for detecting hepatitis B virus (HBV), comprising the composition defined in claim 12 .
15. The antibody of claim 3 , wherein the antibody is a humanized antibody.
16. A polynucleotide coding for the antibody defined in claim 3 .
17. An expression vector comprising the polynucleotide defined in claim 16 .
18. A non-human transformant comprising the expression vector defined in claim 17 .
19. A pharmaceutical composition for preventing or treating hepatitis B virus (HBV) infection, comprising the antibody defined in claim 3 .
20. The pharmaceutical composition of claim 19 , wherein the composition is for preventing or treating hepatitis B.
21. A method of providing information for diagnosis of hepatitis B virus (HBV) infection, comprising:
detecting a pre-S1 protein, which is present in a biological sample isolated from a subject suspected to have HBV infection, through an antigen-antibody reaction using the antibody defined in claim 3 .
22. The method of claim 21 , wherein the method is for providing information for diagnosis of hepatitis B.
23. A composition for detecting hepatitis B virus (HBV), comprising the antibody defined in claim 3 .
24. The composition of claim 23 , wherein the composition is for diagnosis of hepatitis B.
25. A kit for detecting hepatitis B virus (HBV), comprising the composition defined in claim 23 .